Adverse events by grade
| . | Grade 1-2 . | Grade 3-4 . |
|---|---|---|
| Hematologic | ||
| Anemia | 0 | 3 (25%) |
| Neutropenia | 4 (33%) | 0 |
| Thrombocytopenia | 2 (17%) | 0 |
| Nonhematologic | ||
| Acidosis | 0 | 1 (17%) |
| Acute kidney injury | 1 (17%) | 2 (33%) |
| ALT elevation | 1 (17%) | 1 (17%) |
| AST elevation | 3 (50%) | 0 |
| Capillary leak syndrome | 1 (17%) | 1 (17%) |
| Chills | 2 (33%) | 0 |
| Diarrhea | 2 (33%) | 0 |
| Dysgeusia | 2 (33%) | 0 |
| Dyspnea | 2 (33%) | 0 |
| Fall/fracture | 0 | 1 (17%) |
| Fatigue | 3 (50%) | 0 |
| Fever | 4 (66%) | 0 |
| Hemorrhage | 0 | 1 (17%) |
| Hypoalbuminemia | 0 | 1 (17%) |
| Hyponatremia | 0 | 1 (17%) |
| Infection | 3 (50%) | 1 (17%) |
| Maculopapular rash | 3 (50%) | 1 (17%) |
| Multiorgan failure | 0 | 1 (17%) |
| Myositis | 0 | 1 (17%) |
| Pain | 0 | 1 (17%) |
| . | Grade 1-2 . | Grade 3-4 . |
|---|---|---|
| Hematologic | ||
| Anemia | 0 | 3 (25%) |
| Neutropenia | 4 (33%) | 0 |
| Thrombocytopenia | 2 (17%) | 0 |
| Nonhematologic | ||
| Acidosis | 0 | 1 (17%) |
| Acute kidney injury | 1 (17%) | 2 (33%) |
| ALT elevation | 1 (17%) | 1 (17%) |
| AST elevation | 3 (50%) | 0 |
| Capillary leak syndrome | 1 (17%) | 1 (17%) |
| Chills | 2 (33%) | 0 |
| Diarrhea | 2 (33%) | 0 |
| Dysgeusia | 2 (33%) | 0 |
| Dyspnea | 2 (33%) | 0 |
| Fall/fracture | 0 | 1 (17%) |
| Fatigue | 3 (50%) | 0 |
| Fever | 4 (66%) | 0 |
| Hemorrhage | 0 | 1 (17%) |
| Hypoalbuminemia | 0 | 1 (17%) |
| Hyponatremia | 0 | 1 (17%) |
| Infection | 3 (50%) | 1 (17%) |
| Maculopapular rash | 3 (50%) | 1 (17%) |
| Multiorgan failure | 0 | 1 (17%) |
| Myositis | 0 | 1 (17%) |
| Pain | 0 | 1 (17%) |
All grade 3 to grade 4 adverse events and/or any adverse events that were observed in >1 patient are shown. Hematologic events are shown as events observed per patient per cycle and nonhematologic events are shown as the maximum grade observed per patient.
ALT, alanine aminotransferase; AST, aspartate aminotransferase.